

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

KEANEY CONSULTING INC

2. Address:

911 DeWolfe Drive, Alexandria, VA 22308

3. Principal place of business (if different from line 2):

4. Contact Name: DAVID KEANEY

Telephone: 7037806148

E-mail (optional): dkeaney@cox.net

Senate ID #: 313316-36

House ID #:

7. Client Name: Self

NOVARTIS VACCINES & DIAGNOSTICS, INC

TYPE OF REPORT

8. Year 2007 Midyear (January 1 - June 30): **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report: => Termination Date: _____ 11. No Lobbying Activity:

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more: => Income (nearest \$20,000): _____

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more: => Expenses (nearest \$20,000): _____

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- Method A.** Reporting amounts using LDA definitions only
 Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
 Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: KEANEY CONSULTING INC Client Name: NOVARTIS VACCINES & DIAGNOSTICS, INC

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

Prescription Drug User Fees, Drug Safety Issues, Pediatric Drug Issues, Drug Compounding, Direct-to-Consumer Advertising Issues Drug Regulations, Clinical Trials Issues, Vaccine Issues, Pediatric market Exclusivity Issues, Follow-on Biologics Issues, Brazilian Drug Reference Pricing Issue

17. House(s) of Congress and Federal agencies contacted:

Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: KEANEY, DAVID
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.
Novartis Pharma AG Lichtstrasse 35 CH-4056 Basel, Switzerland

Signature: ON FILE Date: Jun 26, 2007

Printed Name and Title: DAVID KEANEY, PRESIDENT, KEANEY CONSULTING INC. -

Information Update Page:

Complete ONLY where registration information has changed.

LOBBYIST UPDATE

23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that NO LONGER pertain

AFFILIATED ORGANIZATIONS

25. Add the following organization(s)

26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization

Signature: ON FILE Date: Jun 26, 2007

Printed Name and Title: -